An observational study to evaluate the impact of treatment strategies and patient-related factors on survival in patients with newly diagnosed Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), and Chronic Myelomonocytic Leukemia (CMML) at institutions participating in the Japan Adult Leukemia Study Group (JALSG)

An observational study to evaluate the impact of treatment strategies and patient-related factors on survival in patients with newly diagnosed Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), and Chronic Myelomonocytic Leukemia (CMML) at institutions participating in the Japan Adult Leukemia Study Group (JALSG) - JALSG-CS-25

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000061136

Enrollment

2000

Registered

2026-04-02

Start date

2026-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or chronic myelomonocytic leukemia (CMML) diagnosed at institutions participating in the Japan Adult Leukemia Study Group (JALSG).

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Age >16 years at the time of informed consent. Newly diagnosed and previously untreated AML (acute myeloid leukemia and related neoplasms), MDS (myelodysplastic syndromes), or CMML (chronic myelomonocytic leukemia) according to the Revised 4th Edition of the WHO Classification. Patients with acute leukemias of ambiguous lineage (acute undifferentiated leukemia and mixed phenotype acute leukemia [MPAL]) and blastic plasmacytoid dendritic cell neoplasm (BPDCN) are also eligible. MDS/MPN (myelodysplastic/myeloproliferative neoplasms) other than CMML are excluded. After receiving a full explanation regarding participation in this study, written informed consent was obtained from the patient (or, in the case of minors or adults with impaired capacity to consent due to cognitive decline, from a legal representative, or from both the patient and the legal representative) based on their full understanding and of their own free will.

Exclusion criteria

Exclusion criteria: If the principal investigator or a co-investigator determines that participation in this study is inappropriate.

Design outcomes

Primary

Measure	Time frame
Overall survival of patients with AML, MDS, or CMML	—

Secondary

Measure	Time frame
Initial treatment efficacy and remission rates by treatment type for AML, MDS, and CMML Relapse-free survival by AML, MDS, and CMML Impact of the use of new drugs on survival rates for AML, MDS, and CMML Impact of the use of supportive care medications on survival rates for AML, MDS, and CMML Evaluation of causes of death Survival rates following allogeneic hematopoietic stem cell transplantation, and the relationship between transplantation methods and relapse-free and graft-versus-host disease (GVHD)-free survival rates Evaluation of transplantation-related complications in allogeneic hematopoietic stem cell transplantation cases Analysis of risk factors affecting overall survival (OS) (impact of patient background, comorbidities, and concomitant medications on treatment outcomes) Impact of genetic information on prognosis	—

Measure

Time frame

Initial treatment efficacy and remission rates by treatment type for AML, MDS, and CMML Relapse-free survival by AML, MDS, and CMML Impact of the use of new drugs on survival rates for AML, MDS, and CMML Impact of the use of supportive care medications on survival rates for AML, MDS, and CMML Evaluation of causes of death Survival rates following allogeneic hematopoietic stem cell transplantation, and the relationship between transplantation methods and relapse-free and graft-versus-host disease (GVHD)-free survival rates Evaluation of transplantation-related complications in allogeneic hematopoietic stem cell transplantation cases Analysis of risk factors affecting overall survival (OS) (impact of patient background, comorbidities, and concomitant medications on treatment outcomes) Impact of genetic information on prognosis

—

Countries

Japan

Contacts

Public ContactEmiko Sakaida

Chiba University Hospital Department of Hematology

ketsueki@office.chiba-u.jp0432227171

Outcome results